Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy
Sponsored by Boston Scientific
As more elderly and co-morbid patients require percutaneous revascularization, 1 year of dual-antiplatelet therapy (DAPT) becomes concerning. This study assessed those in our unit who underwent percutaneous coronary intervention (PCI) with a Synergy stent to examine a minimum of 6 months of clinical outcomes after early discontinuation of DAPT.
(J INVASIVE CARDIOL Epub 2016 December 15)
Rebecca L. Noad, MB, PhD; Colm G. Hanratty, MD; Simon J. Walsh, MD